This newsletter presents you the following key sessions:
1. Podcast with prof. dr. Eric Van Cutsem about the phase II study evaluating trifluridine/tipiracil + bevacizumab
and capecitabine + bevacizumab as first-line treatment of unresectable metastatic colorectal cancer
2. Ipilimumab, nivolumab and panitumumab for chemorefractory KRAS/NRAS/BRAF wild type, microsatellite
stable metastatic colorectal cancer
3. Adjuvant nivolumab does not have a detrimental effect on the quality of life of patients with resected
esophageal or gastroesophageal junction cancer
4. Consistent clinical benefit with atezolizumab-bevacizumab in patients with advanced hepatocellular
carcinoma: updated results of IMbrave150
5. Adding axitinib to octreotide LAR does not significantly delay disease progression in patients with advanced
extra-pancreatic neuroendocrine tumors